



Genizon BioSciences Licenses Ingenuity Pathways Analysis 3.0

Genizon to Integrate the Ingenuity Solution into its Target Express Platform

Montreal, QC and Redwood City, CA – October 25, 2005 - Genizon BioSciences and Ingenuity today announced that they have entered into an agreement for the licensing of Ingenuity Pathways Analysis 3.0, significantly accelerating Genizon's genes-to-targets process.

Genizon will integrate the newest release of Ingenuity Pathways Analysis into its Target Express platform. Genizon conducts whole genome association studies on common diseases to identify the major genes involved in these diseases and their interactions, which provide the basis for comprehensive GeneMaps of the disease. The Ingenuity Pathways Analysis application is being applied to Genizon's lead programs – Crohn's disease, psoriasis, asthma, baldness, and schizophrenia – to identify novel targets in the near term.

Dr. John Hooper, President and CEO of Genizon commented, "Licensing the Ingenuity Pathways Analysis application is another step in our continued efforts to add value to our discoveries by taking the disease genes that we identify downstream to causative biochemical pathways and drug targets. The Ingenuity solution has immediately provided additional discoveries of novel, genetically validated drug targets."

Peter DiLaura, Vice President of Sales and Customer Support at Ingenuity Systems added, "We are very pleased to have Genizon join our rapidly growing list of pharmaceutical, biotechnology, academic and government customers throughout the world. More and more organizations are finding the Ingenuity Pathways Analysis solution to be a necessary technology when attempting to rapidly understand the biological functions and pathways relevant to their experimental data."

Ingenuity Pathways Analysis 3.0 is a next generation pathways tool, enabling life science researchers to model, analyze and understand complex biological systems, and enhancing the productivity of research and development. The application makes use of the Ingenuity Pathways Knowledge Base, the world's largest curated database consisting of millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases.

Fully functional complimentary trials of the NEW Ingenuity Pathways Analysis 3.0 are available to qualified scientists at www.ingenuity.com/trial.

About Genizon BioSciences

Genizon BioSciences is a biotechnology company whose mission is to discover the key disease genes that define causative biochemical pathways for common human diseases, and identify novel targets and predictive biomarkers that will lead to the development of therapeutics and diagnostics that treat the root cause of these diseases and not merely symptoms. Genizon has initiated more than 20 gene discovery programs in several major therapeutic areas including autoimmune, inflammation, metabolism, CNS, respiratory, gastrointestinal, ophthalmology, dermatology, and women's health. www.genizon.com

About Ingenuity®

Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotechnology companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. www.ingenuity.com.

Contacts:

Dr. Bill Cheliak
Vice President, Business Development
Genizon BioSciences Inc.
+1 613 261 9813
bill.cheliak@genizon.com

Lauren Arnold/Wendy Mejia
Schwartz Communications
781.684.0770
genizon@schwartz-pr.com

Elizabeth A. Handlin
Director, Marketing
Ingenuity Systems
650.381.5150
Ingenuity Systems
ehandlin@ingenuity.com

#